13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2026. See the latest, Q2 2026 →
Reported value
$4.02B
+56% on the quarter before
Positions
26
3 new · 6 sold out
Top 10
94.0%
of the value
Est. gain
+$285.7M
on stocks held all quarter
Est. return
+11.4%
on those stocks since Q4 2025
Positions as of Mar 31, 2026, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2025. Striped tiles are options.
Largest buys
Since Q4 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- CME Group~$1.03BNew · 0.0% → 25.6%+3,484,020 shares
- Planet Labs Pbc~$92.4MAdded · 24.4% → 24.5%+3,306,252 shares
- PayPay Corporation~$66.7MNew · 0.0% → 1.7%+3,125,000 shares
- Ethos Technologies Inc~$42.1MNew · 0.0% → 1.0%+3,770,156 shares
Largest sells
Since Q4 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$68.8MSold out · 2.7% → 0.0%−1,036,937 shares
- Revolution Medicines Inc~$5.1MCut · 10.3% → 8.0%−52,577 shares
- Genedx Holdings Corp~$3.0MSold out · 0.1% → 0.0%−22,711 shares
- Exact Sciences Corp~$2.4MSold out · 0.1% → 0.0%−23,205 shares
- Monte Rosa Therapeutics Inc~$998,071Cut · 0.5% → 0.3%−60,673 shares
- Quince Therapeutics Inc~$633,559Sold out · 0.0% → 0.0%−189,122 shares
- Fulcrum Therapeutics Inc~$161,303Sold out · 0.0% → 0.0%−14,262 shares
- Repligen Corp~$62,758Sold out · 0.0% → 0.0%−383 shares
- Relay Therapeutics Inc~$45,571Cut · 0.5% → 0.4%−4,580 shares
Holdings
As of Mar 31, 2026. Changes are in shares against Dec 31, 2025, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CME GroupCOM · shares New | 25.6% | $1.03B | — | ||||||||
| Planet Labs PbcCOM CL A · shares +10% · price +41.7% | 24.5% | $985.2M | +$262.9M | ||||||||
| AST SpaceMobileCOM CL A · shares 0% · price +14.1% | 18.5% | $741.1M | +$91.6M | ||||||||
| Revolution Medicines IncCOM · shares −1.6% · price +22.1% | 8.0% | $320.2M | +$57.9M | ||||||||
| ArmSPONSORED ADS · shares 0% · price +38.4% | 7.4% | $296.6M | +$82.3M | ||||||||
| FreshworksCLASS A COM · shares 0% · price −34.4% | 3.2% | $130.1M | −$68.4M | ||||||||
| UiPathCL A · shares 0% · price −32.3% | 1.9% | $78.1M | −$37.2M | ||||||||
| Tempus AICL A · shares 0% · price −23.4% | 1.7% | $70.1M | −$21.5M | ||||||||
| PayPay CorporationSPONSORED ADS · shares New | 1.7% | $66.7M | — | ||||||||
| GitLabCLASS A COM · shares 0% · price −42.3% | 1.5% | $59.0M | −$43.3M | ||||||||
| Prime Medicine IncCOM · shares 0% · price +0.3% | 1.4% | $57.6M | +$165,625 | ||||||||
| Ethos Technologies IncCL A · shares New | 1.0% | $42.1M | — | ||||||||
| Maze Therapeutics IncCOM · shares 0% · price −28.0% | 1.0% | $41.4M | −$16.1M | ||||||||
| Bridgebio Oncology TherapeutCOM NEW · shares 0% · price −28.5% | 0.63% | $25.3M | −$10.1M | ||||||||
| Relay Therapeutics IncCOM · shares −0.3% · price +17.6% | 0.39% | $15.6M | +$2.3M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares −8.1% · price +4.9% | 0.28% | $11.3M | +$526,892 | ||||||||
| Vera Therapeutics IncCL A · shares 0% · price −20.6% | 0.24% | $9.7M | −$2.5M | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price −29.2% | 0.20% | $8.1M | −$3.3M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price −14.0% | 0.19% | $7.7M | −$1.3M | ||||||||
| Lyell Immunopharma IncCOM NEW · shares 0% · price −34.8% | 0.15% | $5.9M | −$3.1M | ||||||||
| Oscar Health IncCL A · shares 0% · price −20.2% | 0.14% | $5.5M | −$1.4M | ||||||||
| FigmaCLASS A COM STK · shares 0% · price −43.4% | 0.11% | $4.6M | −$3.5M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price +0.4% | 0.05% | $2.1M | +$8,900 | ||||||||
| Hyperfine IncCOM CL A · shares 0% · price +10.2% | 0.02% | $970,618 | +$89,872 | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares 0% · price −30.7% | 0.02% | $963,602 | −$425,939 | ||||||||
| Total · 26 positions | 100% | $4.02B | +$285.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2025 to Q1 2026: 23 stocks held throughout, up $285.7M (+11.4%).
- Planet Labs Pbc+$262.9M+42%
- AST SpaceMobile+$91.6M+14%
- Arm+$82.3M+38%
- Revolution Medicines Inc+$57.9M+22%
- Relay Therapeutics Inc+$2.3M+18%
- Maze Therapeutics Inc−$16.1M−28%
- Tempus AI−$21.5M−23%
- UiPath−$37.2M−32%
- GitLab−$43.3M−42%
- Freshworks−$68.4M−34%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |